Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.

摘要: Abstract Patients with Type 2 diabetes (T2DM) are at high risk of morbidity and mortality from cardiovascular complications, hypoglycaemia increases this risk. Furthermore, other metabolic parameters exacerbate in these patients. The aim the study was to compare effects glimepiride metformin patients T2DM. We evaluated 164 T2DM (80 males, 84 females) a multicentre, randomised, controlled, open, parallel group comparing metformin. Eighty-one (aged 56+/-10 yr) received (3+/-1 mg/d); 83 58+/-9 (2500+/-500 mg/d). had been diagnosed for < or = 6 months; they were non-smokers; no hypertension coronary heart disease; not taking hypolipidaemic drugs, diuretics, beta-blockers thyroxin; normal renal function. Metabolic measured after 12 months treatment. Glimepiride significantly lowered lipoprotein(a) [Lp(a)] homocysteine levels (HCT) months. Both plasminogen activator inhibitor 1 (PAI-1) improved glycosylated haemoglobin, fasting plasma glucose post-prandial Metformin insulin postprandial insulin. also reduced In particular, HCT, Lp(a), PAI-1 levels, important factors atherosclerotic vascular disease. These reductions may be owing metabolism, but it cannot excluded that drugs have direct effect on additional parameters.